comparemela.com

Page 10 - Amplity Health News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SCYNEXIS Announces FDA Approval of BREXAFEMME® (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections

Approval of BREXAFEMME represents the first approved drug in a novel antifungal class in more than 20 yearsBREXAFEMME, a one-day oral treatment for vaginal yeast infection, is the first. | June 2, 2021

Oral vaginal yeast infection treatment Brexafemme gets FDA approval

Jersey City's Scynexis received FDA approval for ibrexafungerp, the first oral treatment for vaginal yeast infection approved in 20+ years.

FDA Approves Ibrexafungerp for Vaginal Yeast Infection

FDA Approves Ibrexafungerp for Vaginal Yeast Infection
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.

Scynexis (NASDAQ:SCYX) - Scynexis Scores FDA Nod For Brexafemme, Oral Treatment For Vaginal Yeast Infection

Scynexis (NASDAQ:SCYX) - Scynexis Scores FDA Nod For Brexafemme, Oral Treatment For Vaginal Yeast Infection
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.